Navigation Links
Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
Date:8/16/2010

n-person">Carmen Perez-Terzic, M.D., Ph.D., of Mayo Clinic; Vinciane Gaussin, Ph.D. and Christian Homsy, M.D., Cardio3 BioSciences, Mont-Saint-Guibert, Belgium; and Jozef Bartunek, M.D., Cardiovascular Center, Aalst, Belgium.

Mayo Clinic and two of the investigators involved in this research have a financial interest associated with technology related to this research. That technology has been licensed to Cardio3 BioSciences in exchange for equity.

1: Behfar A,Yamada S,Crespo-Diaz R, Nesbitt J, Rowe L, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A. Guided Cardiopoiesis Enhances Therapeutic Benefit of Bone Marrow Human Mesenchymal Stem Cells in Chronic Myocardial Infarction. Journal of the American College of Cardiology 2010;under press.

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure(R), is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology licensed from Mayo Clinic, C-Cure is designed to reprogram the patient's own stem cells into new heart cells to rebuild heart tissue.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

About C-CURE and Heart Failure

Heart failure is a serious and common condition in which the heart cannot pump enough blood through the body, leaving the patient debilitated and unable to conduct a normal life. It can result from he
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
4. Signum Biosciences Names Braham Shroot as Chief Executive Officer
5. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
6. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
7. Ambit Biosciences Announces Transition in Company Leadership
8. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
9. Calithera Biosciences Closes $40 Million in Series A Financing
10. MD Biosciences Offers Occlusion-induced Myocardial Infarct Model for Investigating the Cardio-protection of a Drug Treatment in the Event of Ischemia/reperfusion Injury
11. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Cynvenio, a cancer ... through the genomic analysis of tumor cells in the ... a web-based cancer decision support application powered by CollabRx, ... Cynvenio’s ClearID™ genomic test, Therapy Finder will provide breast ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical company, ... the Russian Federation , ... Independent States (CIS). Nemonoxacin is a novel antibiotic for the ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Hi-Bred Biotechnology Leadership ... at Beijing Ag Summit, ... public and private sectors will help increase,farm productivity in the country ... vice president -- DuPont Crop,Genetics Research and Development, told attendees at ...
... 25 IDEXX,Laboratories, Inc. (Nasdaq: IDXX ), today ... 18% to $249.1 million from $211.2 million,for the first ... the,quarter ended March 31, 2008 were $0.43, compared to ... adjusted diluted EPS for the first,quarter grew 21% to ...
... (Nasdaq: KOSN ) will announce its first quarter ... close., The announcement of Kosan,s first quarter 2008 ... live webcast on May 1, 2008 at 1:30,p.m. Pacific ... live,call by dialing 888.680.0878 (US) or 617.213.4855 (international), access,code ...
Cached Biology Technology:DuPont Partnering with China to Increase Farm Productivity 2DuPont Partnering with China to Increase Farm Productivity 3IDEXX Laboratories Announces First Quarter Results 2IDEXX Laboratories Announces First Quarter Results 3IDEXX Laboratories Announces First Quarter Results 4IDEXX Laboratories Announces First Quarter Results 5IDEXX Laboratories Announces First Quarter Results 6IDEXX Laboratories Announces First Quarter Results 7IDEXX Laboratories Announces First Quarter Results 8IDEXX Laboratories Announces First Quarter Results 9IDEXX Laboratories Announces First Quarter Results 10IDEXX Laboratories Announces First Quarter Results 11IDEXX Laboratories Announces First Quarter Results 12IDEXX Laboratories Announces First Quarter Results 13IDEXX Laboratories Announces First Quarter Results 14IDEXX Laboratories Announces First Quarter Results 15IDEXX Laboratories Announces First Quarter Results 16IDEXX Laboratories Announces First Quarter Results 17Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results 2
(Date:4/17/2014)... and Professor Luca Razzari of the nergie Matriaux ... grants from the John R. Evans Leaders Fund ... the acquisition of state-of-the-art biotech and nanophotonics equipment. ... from the Ministre de l,Enseignement suprieur, de la ... (MESRST). These new laboratories will help us develop ...
(Date:4/17/2014)... engineer has developed a patented technique that improves ... The same technique could help police during drug ... Kay L. Theede chair in engineering and department ... research team have created a template-based system that ... The distance detection method called stand-off bomb ...
(Date:4/17/2014)... is available in German . ... the protection money demanded of him, he can expect his ... however, as fear of the consequences is enough to make ... parasitic birds, which lay their eggs in other birds, nests. ... brood parasites take their revenge by destroying the entire nest. ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... the Keck School of Medicine of the University of ... estrogen, the female sex hormone, activates genes in breast-cancer ... to eventually lead to new treatments for the disease. ... of the Keck School,s Department of Biochemistry and Molecular ...
... for rare and neglected diseases that include potential treatments ... virus that affects the central nervous system of newborns, ... and a rare lung disease. The six new projects ... for Rare and Neglected Diseases (TRND) program. "These ...
... Nov. 15, 2011 The Los Angeles World Airports (LAWA), ... has awarded a contract modification to Unisys (NYSE: ... system, used to identify the 45,000 airport employees, contractors, police ... The work is an early step in LAWA,s plan ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2NIH TRND program announces next round of drug development projects 2NIH TRND program announces next round of drug development projects 3NIH TRND program announces next round of drug development projects 4NIH TRND program announces next round of drug development projects 5Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 2Los Angeles World Airports Selects Unisys to Upgrade ID Card Reader System and Network 3
... boxes are ideal for use in refrigerators, freezers, or ... Four vibrant colors allow for color coding to project, ... nitrogen drainage or promote cool air circulation. Supplied with ... 81 tubes. Box dimensions: 13 x 13 ...
RABBIT ANTI BACTERIAL HISTIDASE...
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
See product name for description....
Biology Products: